Introduction {#Sec1}
============

The genus *Ficus* (Moraceae) comprises approximately 1000 species all over the world. They mainly distribute in tropical and subtropical areas and show diversity particularly in Southeast Asia \[[@CR1]\]. In addition to the well-known fig ("Wu Hua Guo") and banyan trees, many *Ficus* plants possess important medicinal values. The plant *Ficus hispida* L.f. is a herbal medicine that has been used in China and India as a remedy for bronchitis, dysentery, rheumatism, and skin disorders \[[@CR2], [@CR3]\]. The extracts from its different parts have been reported to show antiinflammatory, antidiabetic, antitumor, and hepatoprotective activities \[[@CR4]--[@CR7]\]. Primarily known for the rich flavonoids and triterpenoids \[[@CR8]\], alkaloids with antitumor and vasorelaxant activities have also been discovered from *F. hispida* \[[@CR9], [@CR10]\]. Some alkaloids and *α*-glucosidase inhibitory flavonoids from this plant have been reported previously by our group \[[@CR11]\].

Nuclear factor-*κ*B (NF-*κ*B) is a key regulator of inflammation. Activation of NF-*κ*B initiates inflammation-associated metabolic disease, such as obesity, type 2 diabetes, and atherosclerosis \[[@CR12]\]. In order to discover antiinflammatory natural products against metabolic diseases, alkaloid constituents of *F. hispida* were reinvestigated, and their inhibitory effects in NF-*κ*B pathway luciferase assay were evaluated. Seven alkaloids including four new ones (ficuhismines A--D, **1**--**4**) were isolated from the twigs and leaves of *F. hispida* (Fig. [1](#Fig1){ref-type="fig"}). The new compounds represent the first amine alkaloids with a rhamnosyl moiety (**1**--**2)** or with a *N*-oxide motif (**2**--**4**) from the genus *Ficus*. Compound **2** showed potent NF-*κ*B inhibitory activity. In this paper, the structural identification and bioactivity evaluation of the alkaloids are discussed.Fig. 1Structures of compounds **1**--**7**

Results and Discussion {#Sec2}
======================

Compound **1** was assigned the molecular formula C~20~H~31~NO~6~ by the (+)-HRESIMS ion at *m*/*z* 382.2232 \[M+H\]^+^ (calcd for C~20~H~32~NO~6~, 382.2224). The IR spectrum of **1** showed absorption bands for OH (3385 cm^−1^), carbonyl (1675 cm^−1^), and aromatic (1599 cm^−1^) functionalities. The 1D NMR (Table [1](#Tab1){ref-type="table"}) and HSQC spectra displayed signals of a carbonyl group (*δ*~C~ 201.0, C-7), a *para*-substituted benzene ring (*δ*~H~ 7.96, H-9/H-13; 7.13, H-10/H-12; *δ*~C~ 132.3, C-8; 131.4, C-9/C-13; 117.1, C-10/C-12; 161.8, C-11), a rhamnopyranosyl moiety (*δ*~H~ 5.52, H-1′; 3.98, H-2′; 3.81, H-3′; 3.44, H-4′; 3.54, H-5′; 1.18, H~3~-6′; *δ*~C~ 99.6, C-1′; 71.8, C-2′; 72.1, C-3′; 73.7, C-4′; 71.0, C-5′; 18.0, C-6′), a dimethylamino moiety (*δ*~H~ 2.85; *δ*~C~ 43.4), and five methylenes. The anomeric configuration of the [l]{.smallcaps}-rhamnopyranosyl moiety was determined as *α* by the chemical shifts of C-3′ and C-5′ \[[@CR13]\]. The aforementioned information indicated **1** was an amine alkaloid rhamnoside. In the HMBC spectrum (Fig. [2](#Fig2){ref-type="fig"}), the correlations of H~2~-2/Me~2~N, C-3; H~2~-4/C-2, C-3, C-5, C-6; H~2~-6/C-5, C-7; H-9/C-7, C-10, C-11, C-13; and H-10/C-8, C-11, C-12 constructed the aglycone motif as a 6-(dimethylamino)-1-(4-hydroxyphenyl)-1-hexanone. The H-1′/C-11 HMBC correlation indicated that the sugar was connected to C-11. Acid hydrolysis of **1** afforded the aglycone and sugar units. The sugar was verified as [l]{.smallcaps}-rhamnose by TLC analysis and comparing its specific rotation (\[α\]~D~^25^ =  + 6.0) with that of the authentic [l]{.smallcaps}-rhamnose (\[α\]~D~^25^ =  + 8.0). Thus, the structure of **1** was elucidated as depicted, and the compound was given the name ficuhismine A.Table 1^1^H (400 MHz) and ^13^C (150 MHz) NMR data for compounds **1**--**4** (in methanol-*d*~4~)Pos.**1234***δ*~H~ (*J* in Hz)*δ*~C~*δ*~H~ (*J* in Hz)*δ*~C~*δ*~H~ (*J* in Hz)*δ*~C~*δ*~H~ (*J* in Hz)*δ*~C~2H3.10 (m)58.93.63 (m)70.53.61 (m)70.53.43 (m)73.031.72 (m)25.51.92 (m)23.91.90 (m)23.93.04 (m)30.441.43 (m)27.01.47 (m)26.71.45 (m)26.8129.151.74 (m)24.81.78 (m)24.81.76 (m)25.06.67 (br d, 8.0)122.563.01 (t, 6.8)38.63.04 (t, 7.2)38.62.99 (t, 7.2)38.46.70 (d, 8.0)116.77201.0200.9201.0149.58132.3132.3130.0147.397.96 (d, 8.8)131.47.97 (d, 8.8)131.47.87 (d, 8.8)131.86.85 (br s)113.6107.13 (d, 8.8)117.17.15 (d, 8.8)117.16.82 (d, 8.8)116.311161.8161.8163.9127.13 (d, 8.8)117.17.15 (d, 8.8)117.16.82 (d, 8.8)116.3137.96 (d, 8.8)131.47.97 (d, 8.8)131.47.87 (d, 8.8)131.81′5.52 (br s)99.65.53 (br s)99.62′3.98 (br s)71.84.00 (br s)71.83′3.81 (dd, 9.6, 3.2)72.13.82 (dd, 9.3, 3.3)72.24′3.44 (t, 9.6)73.73.46 (overlap)73.75′3.54 (m)71.03.55 (m)71.06′1.18 (d, 6.0)18.01.20 (d, 6.0)18.0Me~2~N2.85 (s)43.43.46 (s)56.43.45 (s)56.43.17 (s)58.6MeO3.82 (s)56.4Fig. 2Key HMBC (H → C) correlations of compounds **1**--**4**

Compound **2** was assigned the molecular formula C~20~H~31~NO~7~ by the (+)-HRESIMS (*m*/*z* 398.2165 \[M+H\]^+^; calcd for C~20~H~32~NO~7~, 398.2173), indicating six indices of hydrogen deficiency. Analysis of its NMR data (Table [1](#Tab1){ref-type="table"}) implied that **2** possessed the same *α*-rhamnopyranosyl and *para*-substituted benzene moieties as **1**. The only difference was the 6-(dimethylamino)-1-hexanone side chain. In the ^13^C NMR spectrum of **2**, the obviously deshielded carbon signals of the dimethylamino moiety (Δ*δ*~C~ + 13.0) and the methylene at C-2 (Δ*δ*~C~ + 11.6) were observed. In consideration the indices of hydrogen deficiency and an additional oxygen atom in the molecular formula of **2**, the presence of a *N*-oxide motif was inferred. The HMBC data shown in Fig. [2](#Fig2){ref-type="fig"} confirmed the structure of **2**. The sugar was identified as [l]{.smallcaps}-rhamnose by the same protocol as that of **1**. Compound **2** was thus elucidated as an *N*-oxide of **2** and named ficuhismine B.

Compound **3** was assigned the molecular formula C~14~H~21~NO~3~ by the (+)-HRESIMS ion at *m*/*z* 252.1595 \[M+H\]^+^ (calcd for C~14~H~22~NO~3~, 252.1594). Its 1D (Table [1](#Tab1){ref-type="table"}) and 2D NMR data (Fig. [2](#Fig2){ref-type="fig"}) indicated that **3** was an aglycone of **2**. The structure of **3** was thus elucidated, and the compound was named ficuhismine C.

Compound **4** was assigned the molecular formula C~11~H~17~NO~3~ by the (+)-HRESIMS ion at *m*/*z* 212.1281 \[M+H\]^+^ (calcd for C~11~H~18~NO~3~, 212.1281). The ^1^H and ^13^C NMR spectra of **4** (Table [1](#Tab1){ref-type="table"}) revealed signals for a dimethylamino moiety, two methylenes, a methoxy group, and a 1, 2, 5-trisubstituted benzene motif. Similar to **2** and **3**, the downfield-shifted ^13^C resonances of the dimethylamino moiety and the methylene at C-2 proved that **4** was also an amino alkaloid *N*-oxide. The HMBC correlations of H~2~-2/Me~2~N, C-3, C-4; H~2~-3/C-4, C-5, C-9; H-9/C-4, C-5, C-7, C-8; and MeO/C-7 (Fig. [2](#Fig2){ref-type="fig"}) confirmed the structure of **4** as depicted. The structure of **4** was thus elucidated, and the compound was named ficuhismine D.

The known compounds were identified as ficushispimine C (**5**) \[[@CR11]\] magnosprengerine (**6**) \[[@CR14]\], and ficushispimine A (**7**) \[[@CR11]\] (Fig. [1](#Fig1){ref-type="fig"}) by comparison of their spectroscopic data with those reported.

All the isolated alkaloids were tested in vitro for their antiinflammatory effects. Ficuhismine B (**2**) exhibited significant inhibitory activity in NF-*κ*B pathway luciferase assay with IC~50~ value of 0.52 ± 0.11 μM. Bortezomib (PS-341) was used as the positive control (IC~50~ = 0.12 ± 0.04 μM) in this test. All the other compounds were inactive. It seemed that both [l]{.smallcaps}-rhamnosyl and *N*-oxide moieties are necessary for the NF-*κ*B inhibition.

Alkaloids are one of the main bioactive ingredients of *F. hispida*. Amphetamine \[[@CR9], [@CR11]\], piperidine \[[@CR9]\], pyrrolidine \[[@CR10], [@CR11]\], and isoquinoline \[[@CR15]\] alkaloids have been reported from this plant previously. In this research, amine alkaloids with a rhamnosyl group (**1**--**2**) or with a *N*-oxide moiety (**2**--**4**) were discovered for the first time from the genus *Ficus*. Compound **2** with both rhamnosyl and *N*-oxide moieties showed potent NF-*κ*B inhibitory activity, which may provide useful information for mining or designing drug leads against inflammation-related metabolic diseases.

Experimental Section {#Sec3}
====================

General Experimental Procedures {#Sec4}
-------------------------------

Optical rotations were recorded on a Rudolph Autopol IV-T polarimeter. UV spectra were recorded on a Hitachi U-2900 UV--Vis spectrophotometer. IR spectra were recorded on a ThermoFisher Nicolet iS5 FT-IR spectrometer. NMR spectra were acquired on Varian Mercury Plus 400 instrument and Bruker Avance III HD 600 spectrometer using CD~3~OD (*δ*~H~ 3.31 and *δ*~C~ 49.0). HRESIMS were obtained on an AB SCIEX 5600+ Q-TOF mass spectrometer. MCI gel CHP-20P (75--150 μm, Mitsubishi Chemical Corporation, Tokyo, Japan), ODS gel (50 μm, YMC Co., Ltd., Japan), and Sephadex LH-20 gel (GE Healthcare Bio-Sciences, USA) were used for column chromatography. Precoated silica gel GF254 plates (Qingdao Haiyang Chemical Co., Ltd., China) were used for TLC analysis. Semi-preparative HPLC was performed on a Shimadzu Essentia LC-16 with a UV detector (210 and 254 nm) and a Kromasil C~18~ column (150 × 10 mm, 5 μm, AkzoNobel, Co., Sweden).

Plant Material {#Sec5}
--------------

The twigs and leaves of *Ficus hispida* were collected in Puer City, Yunnan Province, People's Republic of China, in September 2015. The plant material was identified by Dr. Yun Kang, School of Pharmacy, Fudan University. A voucher specimen (TCM 2015-09-02 Hou) has been deposited at the Herbarium of the Department of Pharmacognosy, School of Pharmacy, Fudan University.

Extraction and Isolation {#Sec6}
------------------------

The plant material (10.0 kg) was ground and percolated with 95% EtOH (30 L) at room temperature. The filtrate was evaporated under reduced pressure to produce a crude extract (1.5 kg). It was dissolved in tartaric acid solution (pH 2.0), basified using saturated sodium carbonate solution to pH 13, and then partitioned with CHCl~3~ to give a total alkaloid extract (1.2 g). This extract was subjected to MCI column chromatography (CC) (MeOH/H~2~O, from 1:9 to 10:0) to provide fractions A--E. Fractions A--D were separated over CC (ODS gel, MeOH/H~2~O, 10:90, 20:80, 30:70, 100:0) to give fractions A1--A4, B1--B4, C1--C4, and D1--D4, respectively. Fr. A1 was loaded on a Sephadex LH-20 column (CH~2~Cl~2~/MeOH, 1:1) and then purified by semi-preparative HPLC (MeOH/H~2~O, 9:91, flow rate 2 mL/min) to afford **3** (2.3 mg, *t*~R~ 16.5 min). Fractions A2 and B1 were purified by semi-preparative HPLC to give **5** (MeCN/H~2~O, 16:84, flow rate 2 mL/min, 2.3 mg, *t*~R~ 23 min) and **7** (MeCN/H~2~O, 6:94, flow rate 2 mL/min, 2.5 mg, *t*~R~ 15 min), respectively. Compounds **4** (MeOH/H~2~O, 3:97, flow rate 4 mL/min, 5.0 mg, *t*~R~ 31 min) and **6** (MeCN/H~2~O, 10:90, flow rate 2 mL/min, 1.5 mg, *t*~R~ 26 min) were isolated by semi-preparative HPLC from fractions C1 and C2, respectively. Compounds **2** (MeOH/H~2~O, 3:97, flow rate 4 mL/min, 2.0 mg, *t*~R~ 31 min) and **1** (MeCN/H~2~O, 11:89, flow rate 4 mL/min, 2.0 mg, *t*~R~16.0 min) were purified by semi-preparative HPLC from fractions D1 and D3, respectively.

Spectroscopic Data of Compounds {#Sec7}
-------------------------------

### Ficuhismine A (1) {#Sec8}

White solid; \[*α*\]~D~^25^ = − 61.0 (*c* 0.1, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 206 (4.28), 262 (4.32) nm; IR (KBr) *ν*~max~ 3385, 2915, 1675, 1599, 1383, 1181, 1141, 1075, 632 cm^−1^; ^1^H NMR and ^13^C NMR data: Table [1](#Tab1){ref-type="table"}; HRESIMS *m/z* 382.2232 \[M+H\]^+^ (calcd for C~20~H~32~NO~6~, 382.2224).

### Ficuhismine B (2) {#Sec9}

White solid; \[*α*\]~D~^25^ = − 70.0 (*c* 0.1, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 206 (4.32), 264 (4.41) nm; IR (KBr) *ν*~max~ 3372, 2935, 1675, 1600, 1421, 1196, 1179, 1140, 1073, 1014, 971, 835 cm^−1^; ^1^H NMR and ^13^C NMR data: Table [1](#Tab1){ref-type="table"}; HRESIMS *m/z* 398.2165 \[M+H\]^+^ (calcd for C~20~H~32~NO~7~, 398.2173).

### Ficuhismine C (3) {#Sec10}

White solid; UV (MeOH) *λ*~max~ (log *ε*) 204 (3.87), 216 (3.90), 274 (4.03) nm; IR (KBr) *ν*~max~ 3412, 2914, 1674, 1604, 1193, 1178, 1142, 1073, 637 cm^−1^; ^1^H NMR and ^13^C NMR data: Table [1](#Tab1){ref-type="table"}; HRESIMS *m/z* 252.1595 \[M+H\]^+^ (calcd for C~14~H~22~NO~3~, 252.1594).

### Ficuhismine D (4) {#Sec11}

White solid; UV (MeOH) *λ*~max~ (log *ε*) 204 (3.81), 216 (3.80), 274 (3.97) nm; IR (KBr) *ν*~max~ 3409, 2950, 2937, 2855, 2581, 1599, 1524, 1454, 1387, 1280, 1033 cm^−1^; ^1^H NMR and ^13^C NMR data: Table [1](#Tab1){ref-type="table"}; HRESIMS *m/z* 212.1281 \[M+H\]^+^ (calcd for C~11~H~18~NO~3~, 212.1281).

Acid Hydrolysis of Compounds 1 and 2 {#Sec12}
------------------------------------

Compound **1** (1 mg) was added to a solution of H~2~O (3 mL), dioxane (3 mL), and HCl (0.5 mL), and then kept at 60 °C for 4 h. The reaction mixture was quenched with NaHCO~3~ and extracted with EtOAc. The aqueous phase was concentrated under reduced pressure. The residue was dissolved in H~2~O for TLC analysis with the authentic [l]{.smallcaps}-rhamnose (EtOAc/MeOH/AcOH/H~2~O, 10:3:3:2, v/v, R~f~: 0.6) and for optical rotation measurement {the aqueous phase: \[α\]~D~^25^ =  + 6.0 (*c* 0.1 H~2~O); [l]{.smallcaps}-rhamnose: \[α\]~D~^25^ =  + 8.0 (*c* 0.1 H~2~O)}. Compound **2** was operated in the same way as **1**.

Luciferase Assay {#Sec13}
----------------

HEK293/NF-*κ*B cells were prepared as reported \[[@CR16]\]. The luciferase assay procedure was performed according to the reported methods \[[@CR17]\]. The IC~50~ values were calculated using Graphpad prism 8.
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